This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tsavachidou, D. Articles by Weber, B. L. Search for Related Content PubMed PubMed Citation Articles by Tsavachidou, D. Articles by Weber, B. L.

SPRY2 Is an Inhibitor of the Ras/Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-Type BRAF but Not with the V599E Mutant

¹ Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania, and ² Mount Sinai School of Medicine, New York, New York

BRAF mutations result in constitutively active BRAF kinase activity and increased extracellular signal-regulated kinase (ERK) signaling and cell proliferation. Initial studies have shown that BRAF mutations occur at a high frequency in melanocytic nevi and metastatic lesions, but recent data have revealed much lower incidence of these mutations in early-stage melanoma, implying that other factors may contribute to melanoma pathogenesis in a wild-type (WT) BRAF context. To identify such contributing factors, we used microarray gene expression profiling to screen for differences in gene expression between a panel of melanocytic and melanoma cell lines with WT BRAF and a group of melanoma cell lines with the V599E BRAF mutation. We found that SPRY2, an inhibitor homologous to SPRY4, which was previously shown to suppress Ras/ERK signaling via direct binding to Raf-1, had reduced expression in WT BRAF cells. Using small interfering RNA-mediated SPRY2 knockdown, we showed that SPRY2 acts as an inhibitor of ERK signaling in melanocytes and WT BRAF melanoma cells, but not in cell lines with the V599E mutation. We also show that SPRY2 and SPRY4 directly bind WT BRAF but not the V599E and other exon 15 BRAF mutants. These data suggest that SPRY2, an inhibitor of ERK signaling, may be bypassed in melanoma cells either by down-regulation of its expression in WT BRAF cells, or by the presence of the BRAF mutation.

This article has been cited by other articles:

				S. C. Brady, M. L. Coleman, J. Munro, S. M. Feller, N. A. Morrice, and M. F. Olson Sprouty2 Association with B-Raf Is Regulated by Phosphorylation and Kinase Conformation Cancer Res., September 1, 2009; 69(17): 6773 - 6781. [Abstract] [Full Text] [PDF]

				C. A. Pratilas, B. S. Taylor, Q. Ye, A. Viale, C. Sander, D. B. Solit, and N. Rosen V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway PNAS, March 17, 2009; 106(11): 4519 - 4524. [Abstract] [Full Text] [PDF]

				M. S. Anglesio, J. M. Arnold, J. George, A. V. Tinker, R. Tothill, N. Waddell, L. Simms, B. Locandro, S. Fereday, N. Traficante, et al. Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors Mol. Cancer Res., November 1, 2008; 6(11): 1678 - 1690. [Abstract] [Full Text] [PDF]

				J. Qi, K. Nakayama, S. Gaitonde, J. S. Goydos, S. Krajewski, A. Eroshkin, D. Bar-Sagi, D. Bowtell, and Z. Ronai The ubiquitin ligase Siah2 regulates tumorigenesis and metastasis by HIF-dependent and -independent pathways PNAS, October 28, 2008; 105(43): 16713 - 16718. [Abstract] [Full Text] [PDF]

				S. Aranda, M. Alvarez, S. Turro, A. Laguna, and S. de la Luna Sprouty2-Mediated Inhibition of Fibroblast Growth Factor Signaling Is Modulated by the Protein Kinase DYRK1A Mol. Cell. Biol., October 1, 2008; 28(19): 5899 - 5911. [Abstract] [Full Text] [PDF]

				B. B. Friday, C. Yu, G. K. Dy, P. D. Smith, L. Wang, S. N. Thibodeau, and A. A. Adjei BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins Cancer Res., August 1, 2008; 68(15): 6145 - 6153. [Abstract] [Full Text] [PDF]

				K. S.M. Smalley, R. Contractor, T. K. Nguyen, M. Xiao, R. Edwards, V. Muthusamy, A. J. King, K. T. Flaherty, M. Bosenberg, M. Herlyn, et al. Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression Cancer Res., July 15, 2008; 68(14): 5743 - 5752. [Abstract] [Full Text] [PDF]

				F. Jaggi, M. A. Cabrita, A.-K. T. Perl, and G. Christofori Modulation of Endocrine Pancreas Development but not {beta}-Cell Carcinogenesis by Sprouty4 Mol. Cancer Res., March 1, 2008; 6(3): 468 - 482. [Abstract] [Full Text] [PDF]

				A. T. Shaw, A. Meissner, J. A. Dowdle, D. Crowley, M. Magendantz, C. Ouyang, T. Parisi, J. Rajagopal, L. J. Blank, R. T. Bronson, et al. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis Genes & Dev., March 15, 2007; 21(6): 694 - 707. [Abstract] [Full Text] [PDF]

				A. Calipel, F. Mouriaux, A.-L. Glotin, F. Malecaze, A.-M. Faussat, and F. Mascarelli Extracellular Signal-regulated Kinase-dependent Proliferation Is Mediated through the Protein Kinase A/B-Raf Pathway in Human Uveal Melanoma Cells J. Biol. Chem., April 7, 2006; 281(14): 9238 - 9250. [Abstract] [Full Text] [PDF]

				D. J. Panka, M. B. Atkins, and J. W. Mier Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clin. Cancer Res., April 1, 2006; 12(7): 2371s - 2375s. [Abstract] [Full Text] [PDF]

				D. J. Panka, W. Wang, M. B. Atkins, and J. W. Mier The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells Cancer Res., February 1, 2006; 66(3): 1611 - 1619. [Abstract] [Full Text] [PDF]

				S. Bloethner, B. Chen, K. Hemminki, J. Muller-Berghaus, S. Ugurel, D. Schadendorf, and R. Kumar Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines Carcinogenesis, July 1, 2005; 26(7): 1224 - 1232. [Abstract] [Full Text] [PDF]